Sanofi, GSK keep the ball rolling with data on second-gen Covid vaccine candidate
Sanofi and GSK are keeping the R&D engine churning for Covid-19 vaccines.
The partners, which have yet to get their first shot on the market …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
